Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Equity Bottom-Up

<ul>
<li>Shares of integrated private healthcare provider <strong><a href="https://www.smartkarma.com/entities/raffles-medical-group-ltd" target="_blank" data-smartkarma-citation="entities:879:1" rel="noopener">Raffles Medical Group (RFMD SP)</a></strong> are currently languishing around a three low. RMG <em>does</em> look attractive compared to regional healthcare plays. </li>
<li>FY23 numbers did no favours - top/bottom line y-o-y contraction of 14.1% and 37.1% respectively.  Yet its emerging China ops show promise. </li>
<li>Of interest is Loo Choon Yong, RMG's founder and major shareholder, who continues adding to his stake, and now holds 54.944%, up from <a href="https://links.sgx.com/FileOpen/_Form%201%20-%20Dr%20Loo%20Choon%20Yong%20-%2028%20February%202024.ashx?App=Announcement&amp;FileID=790183" target="_blank" rel="noopener">53.033%</a> at the beginning of the year.</li>
</ul>


Shares of integrated private healthcare provider Raffles Medical Group (RFMD SP) are currently languishing around a three low. RMG does look attractive compared to regional healthcare plays. 
FY23 numbers did no favours - top/bottom line y-o-y contraction of 14.1% and 37.1% respectively.  Yet its emerging China ops show promise. 
Of interest is Loo Choon Yong, RMG's founder and major shareholder, who continues adding to his stake, and now holds 54.944%, up from 53.033% at the beginning of the year.


Raffles Medical (RFMD SP): Loo Sees A Bargain

Singapore Market Roundup, Singapore Market Roundup

Singapore Market Roundup

Thematic (Sector/Industry)

<ul>
<li>CGS International reduces Venture's target price to $18.94 from $21.78.</li>
<li>Goldman Sachs starts ST Engineering with a 'buy' rating and $13.20 target.</li>
<li>SAC Capital lifts Lincotrade's target price to 52.9 cents, boosting order book.</li>
</ul>


CGS International reduces Venture's target price to $18.94 from $21.78.
Goldman Sachs starts ST Engineering with a 'buy' rating and $13.20 target.
SAC Capital lifts Lincotrade's target price to 52.9 cents, boosting order book.


Singapore Market Roundup (18-Sep-2026): CGS cuts Venture's target price to $18.94 from $21.78.

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

<ul><li>Raffles Medical Group's revenue reached S$765.3 million in 2025, with Profit After Tax and Minority Interests rising 22% to S$38.5 million in 2H25.</li><li>The Group operates three hospitals in China, with the Beijing hospital profitable and others showing steady improvement in services and patient volumes.</li><li>Raffles Medical Group is listed on the Singapore Exchange and operates in 12 cities across five countries in Asia.</li></ul>

Raffles Medical Group's revenue reached S$765.3 million in 2025, with Profit After Tax and Minority Interests rising 22% to S$38.5 million in 2H25.The Group operates three hospitals in China, with the Beijing hospital profitable and others showing steady improvement in services and patient volumes.Raffles Medical Group is listed on the Singapore Exchange and operates in 12 cities across five countries in Asia.

kopi-C with Raffles Medical Group CEO: “There’s no quick money in healthcare”

<ul><li>Singapore Telecommunications led buybacks with 25.5 million shares at S$4.76 each, under a S$2 billion programme.</li><li>Aspial Lifestyle's Chairman increased his stake, acquiring 2,108,300 shares, amid a fund-raising initiative and earnings growth.</li><li>Raffles Medical's Chairman increased his stake to 252,445,223 shares, focusing on China expansion and capital management.</li></ul>

Singapore Telecommunications led buybacks with 25.5 million shares at S$4.76 each, under a S$2 billion programme.Aspial Lifestyle's Chairman increased his stake, acquiring 2,108,300 shares, amid a fund-raising initiative and earnings growth.Raffles Medical's Chairman increased his stake to 252,445,223 shares, focusing on China expansion and capital management.

Directors Increase Stakes, Including Aspial Lifestyle, Raffles Medical and Centurion

<ul><li>RHB sees Raffles Medical's 52-week low as a buying opportunity.</li><li>Citi starts 'buy/high risk' rating on SMID global leader CSE Global.</li><li>Maybank's Seet is bullish on Frencken, lowers target price after $100M placement.</li></ul>

RHB sees Raffles Medical's 52-week low as a buying opportunity.Citi starts 'buy/high risk' rating on SMID global leader CSE Global.Maybank's Seet is bullish on Frencken, lowers target price after $100M placement.

Singapore Market Roundup (10-Sep-2026): RHB views Raffles Medical's 52-week low as a buy signal.

Singapore

Raffles Medical Group is a leading integrated private healthcare provider in Asia. It operates hospitals and a network of medical and dental clinics, offering a wide range of services including primary, specialist, and tertiary care, as well as health insurance and consumer healthcare products. The company was founded in 1976 and is headquartered in Singapore.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Raffles Medical Group (RFMD SP)

Raffles Medical (RFMD SP): Loo Sees A Bargain

Loo buying is positive. I doubt this is a pre-cursor to the family relinquishing control, or a third party takeover. More one of the Loo family...

David Blennerhassett

Singapore Market Roundup (18-Sep-2026): CGS cuts Venture's target price to $18.94 from $21.78.

CGS International cuts Venture's target price to $18.94. Goldman Sachs initiates ST Engineering with a 'buy' and $13.20 target.

Singapore Market Roundup

kopi-C with Raffles Medical Group CEO: “There’s no quick money in healthcare”

Raffles Medical Group's revenue reached S$765.3 million in 2025, with Profit After Tax and Minority Interests rising 22% to S$38.5 million in...

Singapore Exchange Ltd (SGX)

Directors Increase Stakes, Including Aspial Lifestyle, Raffles Medical and Centurion

Singapore Telecommunications led buybacks with 25.5 million shares at S$4.76 each, under a S$2 billion programme. Aspial Lifestyle's Chairman...

Singapore Exchange Ltd (SGX)

Singapore Market Roundup (10-Sep-2026): RHB views Raffles Medical's 52-week low as a buy signal.

RHB views Raffles Medical's 52-week low as a buying chance. Citi gives a 'buy/high risk' rating to CSE Global, while Maybank's Seet is bullish on...

Singapore Market Roundup

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)